• Home
  • Tools
  • TRIPS Flexibilities Database
  • Resources
    • Publications
    • Briefs
    • Useful links
    • Resources en Français
    • All Resources
  • Blog
  • About
Search
Medicines Law & Policy Research and resources on intellectual property and health
  • Home
  • Tools
  • TRIPS Flexibilities Database
  • Resources
    • Publications
    • Briefs
    • Useful links
    • Resources en Français
    • All Resources
  • Blog
  • About

Tag: IFPMA

Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda

Ellen 't Hoen - January 23, 2019

WIPO and pharma industry launch global medicines patent database

Ellen 't Hoen - September 27, 2018

Recent Posts

  • Faced with unreasonable medicines prices, the Netherlands introduces pharmacy exemption in patent law.
  • Cystic Fibrosis Medicines Wars in Europe
  • Cancer Drug Pricing on the World Health Organization’s Executive Board Agenda
  • Time to put a stop to the abuse of orphan drug regulation- the latest scandal

Posts by Subject

Access to Medicines Cancer CDCA competition law Compulsory licensing compulsory licensing for export CRISPR Data exclusivity Delinkage dolutegravir EMA European Commission European Union evergreening France Gilead Hepatitis C HIV IFPMA India innovation Italy LDCs market exclusivity Medicines Patent Pool Medicines Pricing Netherlands Orphan Drugs Patents PrEP R&D rare diseases Scotland Sofosbuvir Spain SPC Supplementary Protection Certificates The Netherlands TRIPS flexibilities Truvada United Kingdom United Nations High Level Panel WHO WIPO WTO
Medicines Law & Policy releases analysis, policy recommendations and tools to aid practitioners working on universal access to medicines. We strive to provide information that is as accurate as possible, and we welcome and encourage feedback. For comments or questions contact us at: info@medicineslawandpolicy.net.
 This work is licensed under Creative Commons.